ADDERALL 30 Drug Patent Profile

When do Adderall 30 patents expire, and what generic alternatives are available?

Adderall 30 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 30 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL 30

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	40
Patent Applications:	1
DailyMed Link:	ADDERALL 30 at DailyMed

Recent Clinical Trials for ADDERALL 30

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boston Children's Hospital	Phase 1
The Beckwith Institute	Phase 4
Eva Szigethy	Phase 4

See all ADDERALL 30 clinical trials

US Patents and Regulatory Information for ADDERALL 30

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ADDERALL 30	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-010	May 12, 1997		DISCN	Yes	No

Expired US Patents for ADDERALL 30

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Womens	ADDERALL 30	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-010	May 12, 1997

International Patents for ADDERALL 30

See the table below for patents covering ADDERALL 30 around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003504406
Australia	6089200
World Intellectual Property Organization (WIPO)	0105407
European Patent Office	1202739
Mexico	PA02000290	FORMA DE DOSIFICACION ORAL DE LIBERACION INMEDIATA RAPIDA. (RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM.)
Canada	2378336

ADDERALL 30 Market Analysis and Financial Projection Experimental

Adderall Drug Market Dynamics and Financial Trajectory

Introduction to Adderall

Adderall, a trade name for the drug amphetamine, is an FDA-approved prescription medication primarily used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is available in both immediate-release and extended-release formulations, making it a versatile treatment option for various patient needs[1][3].

Market Size and Growth

The global Adderall drug market has been experiencing significant growth, driven largely by the increasing prevalence of ADHD. As of 2023, the market size was approximately USD 20.90 billion. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 4% between 2024 and 2032, reaching a value of about USD 29.75 billion by 2032[1][3].

Key Drivers of Market Growth

Rising Prevalence of ADHD

The increasing number of individuals diagnosed with ADHD is a primary driver of the Adderall market. Approximately 4% of adult Americans deal with ADHD symptoms daily, with males being about three times more likely to be diagnosed than females[1].

Aging Population

The growing senior population, which is more vulnerable to neurological illnesses such as Alzheimer's and other cognitive disorders, also contributes to the market growth. The increased use of cognitive medicines for improved physical and mental performance further drives demand[1].

Telehealth and Online Prescriptions

The COVID-19 pandemic has accelerated the adoption of telehealth services, including online prescriptions for controlled substances like Adderall. This shift has expanded access to ADHD treatments, particularly among those who might not have sought traditional in-person care[1].

Market Segmentations

Disease Treatment

The market is segmented by disease treatment, with ADHD being the primary indication. Other uses include narcolepsy and other neurological conditions[3].

Distribution Channels

The market is also segmented by distribution channels, including hospital-based pharmacies, retail pharmacies, and other channels. The availability of Adderall through various distribution channels ensures widespread access to the medication[3].

Regional Markets

North America dominates the Adderall market, followed by Europe and the Asia Pacific region. The high prevalence of ADHD and advanced healthcare infrastructure in North America are key factors driving market growth in this region. The Asia Pacific region is expected to grow at the highest CAGR due to increasing awareness about ADHD and rising healthcare expenditure[1][3].

Financial Performance and Revenue Streams

Historical Revenue

Adderall XR, a significant product in the Adderall family, has been a major revenue generator for companies like Shire. In 2011, Adderall XR achieved revenues of $532 million[2].

Impact of Generic Versions

The introduction of generic versions of Adderall has affected the financial performance of original manufacturers. For instance, the approval of a generic version by Actavis in 2012 led to a 32% decline in Adderall XR sales for Shire during the third quarter of that year[2].

Settlements and Agreements

Companies involved in the Adderall market often engage in legal and financial agreements. For example, Shire paid $48 million to settle claims with Impax regarding the supply of an authorized generic version of Adderall XR[2].

Challenges and Limitations

Side Effects and Contraindications

Adderall has several serious and common side effects, including slow growth in children, seizures, blurred vision, and common issues like headaches, stomachaches, and trouble sleeping. Contraindications include arteriosclerosis, symptomatic cardiovascular disease, and hyperthyroidism, among others[1].

Ethical Concerns

Ethical concerns about the use of stimulant medications can limit market growth. There are debates about the over-prescription of Adderall and its potential misuse, particularly among students and professionals seeking cognitive enhancement[1].

Supply Chain Disruptions

The COVID-19 pandemic has caused supply chain disruptions, leading to shortages of Adderall in some regions. Production delays and worker shortages at key manufacturers like Teva Pharmaceuticals have exacerbated these issues[4].

Future Outlook

Recovery Post-Pandemic

Despite current challenges, the market is expected to recover in the post-pandemic period. The increasing demand for effective ADHD treatments and the expansion of telehealth services will continue to drive market growth[3].

Regional Growth

The Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period, driven by increasing awareness about ADHD and rising healthcare expenditure. North America and Europe will also continue to be significant markets due to their high prevalence of ADHD and advanced healthcare infrastructure[3].

Key Takeaways

• The global Adderall market is driven by the rising prevalence of ADHD and the growing adoption of stimulant medications.
• The market is expected to grow at a CAGR of 4% between 2024 and 2032.
• North America dominates the market, followed by Europe and the Asia Pacific region.
• Supply chain disruptions and ethical concerns are significant challenges.
• The market is expected to recover post-pandemic, driven by increasing demand for ADHD treatments.

Frequently Asked Questions (FAQs)

Q: What is the primary use of Adderall? A: Adderall is primarily used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Q: What is the projected market size of the Adderall drug market by 2032? A: The market is expected to reach a value of about USD 29.75 billion by 2032.

Q: Which region dominates the Adderall market? A: North America dominates the Adderall market, followed by Europe and the Asia Pacific region.

Q: What are some of the common side effects of Adderall? A: Common side effects include headaches, stomachaches, trouble sleeping, decreased appetite, nervousness, and dizziness.

Q: How has the COVID-19 pandemic affected the Adderall market? A: The pandemic has led to supply chain disruptions and increased demand for telehealth services, which has expanded access to ADHD treatments but also caused shortages in some regions.

Cited Sources

1. Expert Market Research - Adderall Drug Market Size, Share | Industry Statistics 2032
2. PMLive - Shire pays $48m to settle generic Adderall XR claims with Impax
3. Research and Markets - Adderall Drug Market Report and Forecast 2023-2031
4. Boston University - What's Behind the Adderall Shortage and What Does It Mean for Patients?